Delivery Order SPE2DB22D3016-SPE2DB26FABE0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xcopri 100 mg tablets in quantities of 30 units, with a ceiling value of $2,357.92 and an ultimate completion date of August 11, 2025. This competitively awarded, non-set-aside contract utilized firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Xcopri 150 mg tablets (30-count units) with a ceiling value of $6,848.28. This firm fixed-price delivery order, with an ultimate completion date of November 5, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Xcopri 100 mg tablets in a quantity of 30 units, with a contract ceiling value of $2,338.28. This is a firm fixed-price delivery order with an ultimate completion date of September 25, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Xcopri 100 mg tablets (30-count packaging) valued at $1,037.97. This firm fixed-price delivery order, with an ultimate completion date of August 18, 2025, represents a competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xcopri 200 mg tablets (30-count units) on May 20, 2025, with an ultimate completion date of May 21, 2025. This firm fixed-price delivery order, valued at $1,768.44, represents a non-set-aside competitive award and will be performed at the contractor's Conshohocken, Pennsylvania facility. The contract is issued as a child order under AmerisourceBergen's larger pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,413.60 on August 25, 2025, for the supply of Xcopri 200 mg tablets (30-count). The contract is classified as a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this order. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xcopri 50 mg tablets (30-count) with a ceiling value of $2,070.10. This competitive award utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation, indicating it...
- The Defense Logistics Agency awarded a $4,857.44 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Xcopri 50 mg tablets (30-count units). This firm fixed-price contract, with an ultimate completion date of June 2, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract was competitively awarded with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 20, 2025, for the supply of Xcopri 200 mg tablets (30-count units) under a firm fixed-price contract valued at $2,820.90. This is a non-set-aside award, indicating the contract was competitively awarded. The delivery order is associated with AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Xcopri 200 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $1,757.77. This is a non-set-aside competitive award with an ultimate completion date of November 10, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FABE0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Xcopri 200 mg tablets (30-count packaging) under a firm fixed-price contract valued at $1,684.59. This is a non-set-aside award, indicating the contract was competitively bid. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of November 4, 2025. This delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's substantial IDC with DLA enables it to supply a comprehensive range of pharmaceutical products across multiple therapeutic domains to support Defense Health Agency operations and other government healthcare systems worldwide. This specific delivery order for Xcopri, an anti-epileptic medication, exemplifies the company's role in fulfilling pharmaceutical supply needs through the DLA's medical supply chain logistics network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 11/3/25 |